Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation Successfully Treated
Emiliano Javier Bertone1,2, Martin Milanesio1,2, Mercedes de Jesus Garcia1,2
1Hematology and Oncology Service, Hospital Privado Universitario de Cordoba, Argentina.
Abstract:
Pure red cell aplasia (PRCA) is a potential complication after ABO-incompatible allogeneic hematopoietic stem cell transplantation (HCT). In case where PRCA persists beyond 60 days post-HCT, spontaneous resolution is rare, and therapeutic intervention is typically required. However, there is currently no established standard of care for its management. We report two cases of post-transplant PRCA that were refractory to conventional therapies, including erythropoietin and rituximab, and were successfully treated with daratumumab. These cases underscore the potential role of daratumumab as an effective therapeutic option in the management of PRCA following ABO-incompatible HCT. Given the limited data available on its use in this setting, our report contributes with valuable clinical evidence supporting its efficacy and safety.
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:15Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...